Viking Therapeutics ($VKTX) Gains Attention with Positive Fatty Liver Disease Drug Data Amid Stock Fluctuations and Investor Concerns

Viking Therapeutics ($VKTX) is attracting attention in the biotech sector due to positive data on its fatty liver disease drug. The company's stock has seen fluctuations, with some investors pointing to potential replacements for its drugs. VKTX emphasizes the importance of drug tolerability and safety profiles, leading in these aspects. Recent data shows promising results in NASH resolution and efficacy. VKTX's upcoming milestones include FDA responses, oral drug updates, and MASH data. Despite market fluctuations and concerns, VKTX remains a focus for investors.